CA3183551A1 - Pyridine-1,5-diones exhibiting mnk inhibition and their method of use - Google Patents
Pyridine-1,5-diones exhibiting mnk inhibition and their method of useInfo
- Publication number
- CA3183551A1 CA3183551A1 CA3183551A CA3183551A CA3183551A1 CA 3183551 A1 CA3183551 A1 CA 3183551A1 CA 3183551 A CA3183551 A CA 3183551A CA 3183551 A CA3183551 A CA 3183551A CA 3183551 A1 CA3183551 A1 CA 3183551A1
- Authority
- CA
- Canada
- Prior art keywords
- compound
- alkyl
- cycloalkyl
- mmol
- compounds
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/20—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/14—Ortho-condensed systems
- C07D491/147—Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/20—Spiro-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Epidemiology (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pyridine Compounds (AREA)
- Steroid Compounds (AREA)
- Cosmetics (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063046325P | 2020-06-30 | 2020-06-30 | |
| US63/046,325 | 2020-06-30 | ||
| PCT/US2021/039982 WO2022006331A2 (en) | 2020-06-30 | 2021-06-30 | Pyridine-1,5-diones exhibitng mnk inhibition and their method of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3183551A1 true CA3183551A1 (en) | 2022-01-06 |
Family
ID=79315594
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3183551A Pending CA3183551A1 (en) | 2020-06-30 | 2021-06-30 | Pyridine-1,5-diones exhibiting mnk inhibition and their method of use |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230286983A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4171565A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2023533616A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230041715A (cg-RX-API-DMAC7.html) |
| CN (1) | CN116194112A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021300363A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112022026275A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3183551A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL299512A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2022016516A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022006331A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4363419A4 (en) * | 2021-06-30 | 2025-06-11 | 4E Therapeutics, Inc. | Spirocyclic pyridine-1,5-diones exhibiting mnk inhibition and their method of use |
| EP4646266A1 (en) * | 2023-01-04 | 2025-11-12 | 4E Therapeutics, Inc. | Solid state forms of mnk inhibitors |
| WO2026006417A1 (en) * | 2024-06-26 | 2026-01-02 | 4E Therapeutics, Inc. | Formulations of mnk inhibitors |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2012009735A (es) * | 2010-02-26 | 2012-09-12 | Boehringer Ingelheim Int | 4-[cicloalquiloxi (hetero) arilamino] tieno [2,3-d] pirimidinas que tienen actividad inhibitoria de mnk1/mnk2 para composiciones farmaceuticas. |
| RU2014111055A (ru) * | 2011-08-22 | 2015-09-27 | Мерк Шарп И Доум Корп. | 2-спирозамещенные иминотиазины и их моно- и диоксиды в качестве ингибиторов bace, композиции и их применение |
| GB201205669D0 (en) * | 2012-03-30 | 2012-05-16 | Agency Science Tech & Res | Bicyclic heterocyclic derivatives as mnk2 and mnk2 modulators and uses thereof |
| TWI713455B (zh) * | 2014-06-25 | 2020-12-21 | 美商伊凡克特治療公司 | MnK抑制劑及其相關方法 |
| JP2018531266A (ja) * | 2015-10-22 | 2018-10-25 | セルビタ エス.エー. | ピリドン誘導体およびキナーゼ阻害剤としてのその使用 |
| CA3002558A1 (en) * | 2015-10-29 | 2017-05-04 | Effector Therapeutics, Inc. | Pyrrolo-, pyrazolo-, imidazo-pyrimidine and pyridine compounds that inhibit mnk1 and mnk2 |
| GB201520500D0 (en) * | 2015-11-20 | 2016-01-06 | Medical Res Council Technology | Compounds |
| JP2019510061A (ja) * | 2016-03-31 | 2019-04-11 | サウス オーストラリアン ヘルス アンド メディカル リサーチ インスティテュート リミテッドSouth Australian Health And Medical Research Institute Limited | 高脂肪食関連疾患を阻害する方法 |
| CA3064000A1 (en) * | 2017-05-24 | 2018-11-29 | Effector Therapeutics, Inc. | Methods and compositions for cellular immunotherapy |
| EP3870178A4 (en) * | 2018-10-24 | 2022-08-03 | Effector Therapeutics Inc. | Crystalline forms of mnk inhibitors |
| CN111484494B (zh) * | 2019-01-29 | 2022-09-13 | 诺沃斯达药业(上海)有限公司 | 抑制mnk1和mnk2的多环化合物 |
| EP3972593B1 (en) * | 2019-05-23 | 2025-07-02 | Board of Regents, The University of Texas System | Inhibitor of mnk for the treatment of neuropathic pain |
| CN110256432A (zh) * | 2019-06-27 | 2019-09-20 | 诺沃斯达药业有限公司 | 抑制mnk1和mnk2的多环化合物 |
-
2021
- 2021-06-30 WO PCT/US2021/039982 patent/WO2022006331A2/en not_active Ceased
- 2021-06-30 JP JP2023524490A patent/JP2023533616A/ja active Pending
- 2021-06-30 CA CA3183551A patent/CA3183551A1/en active Pending
- 2021-06-30 BR BR112022026275A patent/BR112022026275A2/pt unknown
- 2021-06-30 KR KR1020237003174A patent/KR20230041715A/ko active Pending
- 2021-06-30 US US18/003,829 patent/US20230286983A1/en active Pending
- 2021-06-30 IL IL299512A patent/IL299512A/en unknown
- 2021-06-30 EP EP21831750.1A patent/EP4171565A4/en active Pending
- 2021-06-30 AU AU2021300363A patent/AU2021300363A1/en active Pending
- 2021-06-30 MX MX2022016516A patent/MX2022016516A/es unknown
- 2021-06-30 CN CN202180056845.0A patent/CN116194112A/zh active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2022006331A9 (en) | 2022-03-03 |
| KR20230041715A (ko) | 2023-03-24 |
| MX2022016516A (es) | 2023-03-28 |
| WO2022006331A3 (en) | 2022-02-10 |
| JP2023533616A (ja) | 2023-08-03 |
| WO2022006331A8 (en) | 2023-03-16 |
| EP4171565A4 (en) | 2024-11-27 |
| US20230286983A1 (en) | 2023-09-14 |
| EP4171565A2 (en) | 2023-05-03 |
| CN116194112A (zh) | 2023-05-30 |
| WO2022006331A2 (en) | 2022-01-06 |
| BR112022026275A2 (pt) | 2023-03-14 |
| AU2021300363A1 (en) | 2023-02-09 |
| IL299512A (en) | 2023-02-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12110292B2 (en) | Ligands to cereblon (CRBN) | |
| US12398141B2 (en) | JAK kinase inhibitor, preparation method for same, and applications thereof in field of medicine | |
| US9314468B2 (en) | Chemokine receptor modulators | |
| US12030892B2 (en) | CRBN modulators | |
| US11766435B2 (en) | N3-substituted iminopyrimidinones as antimalarial agents | |
| US20250205244A1 (en) | Methods of treating migraine with mnk inhibitors | |
| AU2015402778B2 (en) | Aminonapthoquinone compounds and pharmaceutical composition for blocking ubiquitination-proteasome system in diseases | |
| US20250186436A1 (en) | Spirocyclic pyridine-1,5-diones exhibiting mnk inhibition and their method of use | |
| US20230286983A1 (en) | Pyridine-1,5-diones exhibiting mnk inhibition and their method of use | |
| KR20230069984A (ko) | Tyk2 억제제 및 그의 용도 | |
| US9975888B2 (en) | Aryl linked imidazole and triazole derivatives and methods of use thereof for improving the pharmacokinetics of a drug | |
| US20240400551A1 (en) | Nek7 inhibitors | |
| US20230118751A1 (en) | Fused ring compound and application thereof | |
| WO2022226182A1 (en) | Nek7 inhibitors | |
| TW202523670A (zh) | Pde 7調節劑化合物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| P22 | Classification modified |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P22-P110 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CLASSIFICATION MODIFIED Effective date: 20241114 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED Effective date: 20250617 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250617 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD Year of fee payment: 4 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250620 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250620 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250826 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT Effective date: 20250826 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250827 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20260528 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD Year of fee payment: 5 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20260626 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20260626 |